Product of natural evolution (SARS, MERS, and SARS-CoV-2); deadly diseases, from SARS to SARS-CoV-2

被引:19
|
作者
Shahrajabian, Mohamad Hesam [1 ]
Sun, Wenli [1 ]
Cheng, Qi [1 ,2 ,3 ]
机构
[1] Chinese Acad Agr Sci, Biotechnol Res Inst, Beijing, Peoples R China
[2] Hebei Agr Univ, Coll Life Sci, Baoding, Hebei, Peoples R China
[3] Global Alliance HeBAU CLS & HeQiS BioAl Mfg, Baoding, Hebei, Peoples R China
关键词
SARS; coronaviruses; SARS-CoV-2; MERS; pneumonia; emerging diseases; RESPIRATORY SYNDROME-CORONAVIRUS; RECEPTOR-BINDING DOMAIN; DIPEPTIDYL PEPTIDASE 4; ELICITS HIGH TITERS; SPIKE PROTEIN; 2019; COVID-19; IN-VITRO; IMMUNE-RESPONSES; SAUDI-ARABIA; FUNCTIONAL-CHARACTERIZATION;
D O I
10.1080/21645515.2020.1797369
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
SARS-CoV-2, the virus causing COVID-19, is a single-stranded RNA virus belonging to the order Nidovirales, family Coronaviridae, and subfamily Coronavirinae. SARS-CoV-2 entry to cellsis initiated by the binding of the viral spike protein (S) to its cellular receptor. The roles of S protein in receptor binding and membrane fusion makes it a prominent target for vaccine development. SARS-CoV-2 genome sequence analysis has shown that this virus belongs to the beta-coronavirus genus, which includes Bat SARS-like coronavirus, SARS-CoV and MERS-CoV. A vaccine should induce a balanced immune response to elicit protective immunity. In this review, we compare and contrast these three important CoV diseases and how they inform on vaccine development.
引用
收藏
页码:62 / 83
页数:22
相关论文
共 50 条
  • [1] SARS-CoV, MERS-CoV and SARS-CoV-2: A Diagnostic Challenge
    Ezhilan, Madeshwari
    Suresh, Indhu
    Nesakumar, Noel
    [J]. MEASUREMENT, 2021, 168
  • [2] The evolution of SARS-CoV-2
    Peter V. Markov
    Mahan Ghafari
    Martin Beer
    Katrina Lythgoe
    Peter Simmonds
    Nikolaos I. Stilianakis
    Aris Katzourakis
    [J]. Nature Reviews Microbiology, 2023, 21 : 361 - 379
  • [3] The evolution of SARS-CoV-2
    Markov, Peter V.
    Ghafari, Mahan
    Beer, Martin
    Lythgoe, Katrina
    Simmonds, Peter
    Stilianakis, Nikolaos I.
    Katzourakis, Aris
    [J]. NATURE REVIEWS MICROBIOLOGY, 2023, 21 (06) : 361 - 379
  • [4] SARS-CoV-2 evolution
    Devi, Sharmila
    [J]. LANCET INFECTIOUS DISEASES, 2021, 21 (04): : 467 - 467
  • [5] Human Coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 in Children
    Aleebrahim-Dehkordi, Elahe
    Soveyzi, Faezeh
    Deravi, Niloofar
    Rabbani, Zahra
    Saghazadeh, Amene
    Rezaei, Nima
    [J]. JOURNAL OF PEDIATRIC NURSING-NURSING CARE OF CHILDREN & FAMILIES, 2021, 56 : 70 - 79
  • [6] Data mining of coronavirus: SARS-CoV-2, SARS-CoV and MERS-CoV
    Huh, Jung Eun
    Han, Seunghee
    Yoon, Taeseon
    [J]. BMC RESEARCH NOTES, 2021, 14 (01)
  • [7] The Pathogenicity of MERS-CoV, SARS-CoV and SARS-CoV-2: A Comparative Overview
    Shashank, Patil M.
    Prithvi, Shirahatti S.
    Ramith, Ramu
    [J]. RESEARCH JOURNAL OF BIOTECHNOLOGY, 2021, 16 (01): : 182 - 192
  • [8] Data mining of coronavirus: SARS-CoV-2, SARS-CoV and MERS-CoV
    Jung Eun Huh
    Seunghee Han
    Taeseon Yoon
    [J]. BMC Research Notes, 14
  • [9] Diabetes and coronavirus infections (SARS-CoV, MERS-CoV, and SARS-CoV-2)
    Navand, Azadeh Haghi
    Soltani, Saber
    Moghadami, Mona
    Hosseini, Parastoo
    Nasimzadeh, Sepideh
    Zandi, Milad
    [J]. JOURNAL OF ACUTE DISEASE, 2020, 9 (06) : 244 - 247
  • [10] Mapping the technological landscape of SARS, MERS, and SARS-CoV-2 vaccines
    Nascimento Junior, Jose Adao Carvalho
    Santos, Anamaria Mendonca
    Cavalcante, Rafael Ciro Marques
    Quintans-Junior, Lucindo Jose
    Walker, Cristiani Isabel Bandero
    Borges, Lysandro Pinto
    Frank, Luiza Abrahao
    Serafini, Mairim Russo
    [J]. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2021, 47 (04) : 673 - 684